Acute myeloid leukemia (AML) is a heterogeneous disease with diverse genetic abnormalities and variable response to treatment. In the last decade the diverse genetic abnormalities have refined risk-stratification of AML.[1][1] Recently, mutations in the Casitas B-cell lymphoma gene encoding the E3-
No takes yet. Share an insight, caveat, or question.
Abbas et al. (2008) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: